Chimeric Newcastle disease viruses and uses thereof
Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
1. A method for treating cancer in a subject, comprising administering to a subject in need thereof a pharmaceutical composition comprising a first chimeric NDV and a pharmaceutically acceptable carrier, wherein the first chimeric NDV comprises a packaged genome which encodes a heterologous interferon antagonist, so that the heterologous interferon antagonist is expressed by the virus.
2. The method of claim 1 , wherein the packaged genome of the first chimeric NDV encodes a modified F protein with a mutated cleavage site, so that the modified F protein is expressed by the virus.
3. The method of claim 1 , wherein the packaged genome of the first chimeric NDV encodes a tumor antigen, so that the tumor antigen is expressed by the virus.
4. The method of claim 2 , wherein the packaged genome of the first chimeric NDV encodes a tumor antigen, so that the tumor antigen is expressed by the virus.
5. The method of claim 1 , wherein the heterologous interferon antagonist is an influenza virus NS1 protein.
6. The method of claim 2 , wherein the heterologous interferon antagonist is an influenza virus NS1 protein, Nipah virus W protein, Nipah V protein, Ebola virus VP35 protein, Vaccinia virus E3L protein, RSV NS2 protein or Hepatitis C virus NS3-4 protease.
7. The method of claim 1 , wherein the heterologous interferon antagonist is Nipah virus W protein, Nipah V protein, Ebola virus VP35 protein, Vaccinia virus E3L protein, RSV NS2 protein or Hepatitis C virus NS3-4 protease.
8. The method of claim 1 , further comprising administering to the subject a second chimeric NDV, wherein the second chimeric NDV comprises a packaged genome which encodes interleukin-2 (IL-2), so that the IL-2 is expressed by the virus.
9. The method of claim 1 , further comprising administering to the subject a second chimeric NDV, wherein the second chimeric NDV comprises a packaged genome which encodes IL-2 and a modified F protein with a mutated cleavage site, so that the IL-2 and the modified F protein are expressed by the virus.
10. The method of claim 1 , wherein the cancer is melanoma, colorectal cancer, breast cancer, ovarian cancer or renal cell cancer.
11. The method of claim 1 , wherein the cancer is malignant melanoma, malignant glioma, renal cell carcinoma, pancreatic adenocarcinoma, malignant mesothelioma, lung adenocarcinoma, lung small cell carcinoma, lung squamous cell carcinoma, anaplastic thyroid cancer or head and neck squamous cell carcinoma.
12. The method of claim 2 , wherein the heterologous interferon antagonist is an influenza virus NS1 protein.
13. The method of claim 2 , wherein the cancer is melanoma, colorectal cancer, breast cancer, ovarian cancer or renal cell cancer.
14. The method of claim 2 , wherein the cancer is malignant melanoma, malignant glioma, renal cell carcinoma, pancreatic adenocarcinoma, malignant mesothelioma, lung adenocarcinoma, lung small cell carcinoma, lung squamous cell carcinoma, anaplastic thyroid cancer or head and neck squamous cell carcinoma.
15. The method of claim 3 , wherein the cancer is melanoma, colorectal cancer, breast cancer, ovarian cancer or renal cell cancer.
16. The method of claim 3 , wherein the cancer is malignant melanoma, malignant glioma, renal cell carcinoma, pancreatic adenocarcinoma, malignant mesothelioma, lung adenocarcinoma, lung small cell carcinoma, lung squamous cell carcinoma, anaplastic thyroid cancer or head and neck squamous cell carcinoma.